Best for
Mobile

Posted
Redx Pharma Plc is a biotechnology business based in the UK. Redx Pharma shares (REDX.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Its last market close was 57p – a decrease of 5% over the previous week. Redx Pharma employs 52 staff and has a trailing 12-month revenue of around £4.3 million.
Best for
Mobile
Best for
Low-cost
Best for
All rounder
Best for
Beginners
Since the stock market crash in March caused by coronavirus, Redx Pharma's share price has had significant positive movement.
Its last market close was 57p, which is 85.53% up on its pre-crash value of 8.25p and 1,166.67% up on the lowest point reached during the March crash when the shares fell as low as 4.5p.
If you had bought £1,000 worth of Redx Pharma shares at the start of February 2020, those shares would have been worth £1,931.03 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £7,862.07.
Latest market close | 57p |
---|---|
52-week range | 4.4977p - 76.8207p |
50-day moving average | 58.0374p |
200-day moving average | 49.3118p |
Wall St. target price | 65p |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | -5.2p |
Other fees may apply. Your capital is at risk.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of 55.5p
1 month (2020-12-22) | 5.71% |
---|---|
3 months (2020-10-22) | -17.78% |
Revenue TTM | £4.3 million |
---|---|
Gross profit TTM | £2.8 million |
Return on assets TTM | -49.22% |
Return on equity TTM | -212.06% |
Profit margin | -138.95% |
Book value | 0.012p |
Market capitalisation | £158.9 million |
TTM: trailing 12 months
We're not expecting Redx Pharma to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Redx Pharma's shares have ranged in value from as little as 4.4977p up to 76.8207p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Redx Pharma's is 0.2444. This would suggest that Redx Pharma's shares are less volatile than average (for this exchange).
Subscribe to trending stock alerts for a chance to win
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company is developing RXC004, a porcupine inhibitor, which is in Phase I clinical development for the treatment of colorectal, pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory disease related fibrosis; ROCK2, a Rho-associated protein kinase 2 inhibitor for the treatment of diabetic nephropathy, and idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH)/liver fibrosis; and Porcupine (RXC006), a drug for IPF, NASH, and liver fibrosis. It is also developing Pan-RAF inhibitor for colorectal cancer; SHP2, a protein-tyrosine phosphatase for receptor tyrosine kinase signaling in cancer cells; and RXC005, a reversible inhibitor of Bruton's tyrosine kinase. Redx Pharma Plc has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. The company was founded in 2010 and is based in Macclesfield, the United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.